

What is claimed is:

1. A process for detecting the presence or absence of methylation of a CpG dinucleotide rich region of a nucleic acid sequence within a genome, the process comprising:
 - 5 a. contacting the nucleic acid sequence with an enzyme which digests the nucleic acid sequences into fragments in which CpG islands are preserved;
 - b. attaching the fragments to linker primers to form linker primer products;
 - 10 c. contacting the linker primer products with a methylation-sensitive enzyme which digests the linker products having unmethylated CpG dinucleotide sequences but not methylated CpG dinucleotide sequences to form a digestion product comprising
 - 15 methylated CpG island loci;
 - d. amplifying the digestion product to form amplicons;
 - e. labeling the amplicons;
 - f. contacting the labeled amplicons with a screening array comprising a plurality of nucleic acid
 - 20 fragments affixed to a solid support; and
 - g. determining the presence or absence of labeled amplicons bound to the plurality of nucleic acid fragments affixed to the solid support of the screening array.

2. The process of claim 1 wherein the plurality of nucleic acid fragments affixed to the solid support of the screening array are derived from a CpG dinucleotide rich genomic library.
3. The process of claim 2 wherein the nucleic acid fragments affixed to the solid support of the screening array are CpG dinucleotide rich fragments which comprise a sequence of at least about 200 nucleotides of which at least about
5 50% are guanine and cytosine.
4. The process of claim 3 wherein at least 20 nucleic acid fragments are affixed to the solid support of the screening array.
5. The process of claim 3 wherein the plurality of nucleic acid fragments affixed to the solid support of the screening array each contain a promoter and a first exon of a gene.
6. The process of claim 5 wherein the plurality of nucleic acid fragments affixed to the solid support of the screening array each comprise a nucleic acid sequence which is expressed in an organism.
7. The process of claim 6 wherein at least 20 nucleic acid fragments are affixed to the solid support of the screening array.

8. The process of claim 7 wherein at least 100 nucleic acid fragments are affixed to the solid support of the screening array.
9. The process of claim 8 wherein at least 500 nucleic acid fragments are affixed to the solid support of the screening array.
10. The process of claim 1 wherein the solid support of the screening array comprises nylon, glass or silicon.
11. The process of claim 1 wherein the label is selected from the group consisting of radioisotopes and fluorescent labels.
12. The process of claim 1 wherein the enzyme is selected from the group consisting of MseI, Tsp509I, NlaIII and BfaI and the methylation sensitive enzyme is selected from the group consisting of BstU I, SmaI, SacII, EagI, MspI, HpaII, HhaI and BssHII.
13. The process of claim 12 wherein the enzyme is MseI and the methylation sensitive enzyme is BstU I.
14. The process of claim 1 wherein said process is used for diagnosing and monitoring the prognosis of a disease associated with aberrant DNA methylation.

15. The process of claim 14 wherein said disease is breast cancer, prostate cancer, colon cancer, lung cancer, liver cancer and ovarian cancer.
16. The process of claim 15 wherein the disease is breast cancer.
17. The process of claim 16 wherein the CpG island fragments affixed on the solid support of the screening array are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.
18. A screening array comprising a solid support and a plurality of nucleic acid fragments affixed to the solid support wherein each nucleic acid fragment of the plurality of the nucleic acid fragments is a CpG

dinucleotide rich fragment which comprises a sequence of at least about 200 nucleotides of which at least about 50% are guanine and cytosine.

19. The screening array of claim 18 wherein the plurality of nucleic acid fragments affixed to the solid support are derived from a CpG dinucleotide rich genomic library.
20. The screening array of claim 19 wherein at least 20 nucleic acid fragments are affixed to the solid support.
21. The process of claim 19 wherein the plurality of nucleic acid fragments affixed to the solid support each contain a promoter and a first exon of a gene.
22. The screening array of claim 21 wherein at least 20 nucleic acid fragments are affixed to the solid support.
23. The screening array of claim 22 wherein at least 100 nucleic acid fragments are affixed to the solid support.
24. The screening array of claim 23 wherein at least 500 nucleic acid fragments are affixed to the solid support.
25. The screening array of claim 18 wherein the solid support comprises nylon, glass or silicon.

26. The screening array of claim 18 wherein the plurality of nucleic acid fragments affixed on the solid support are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.
27. A process for generating a screening array containing expressed gene sequences, said process comprising the steps of:
 - a. contacting a nucleic acid sequence with an enzyme which digests the nucleic acid sequence into fragments in which CpG islands are preserved;
 - b. amplifying the fragments to form a plurality of CpG island fragments;

UMO 1523
PATENT

- c. screening the plurality of CpG island fragments with a nucleic acid probe to identify CpG island fragments which contain expressed sequences; and
 - d. affixing the CpG island fragments which contain expressed sequences onto a solid support.
- 5
28. The process of claim 27 wherein the nucleic acid sequence is derived from a CpG dinucleotide rich genomic library.
29. The process of claim 28 wherein the CpG island fragments which contain expressed sequences are CpG dinucleotide rich fragments which comprise a sequence of at least about 200 nucleotides of which at least about 50% are
- 5 guanine and cytosine.
30. The process of claim 29 wherein at least 20 CpG island fragments which contain expressed sequences are affixed to the solid support.
31. The process of claim 29 wherein the CpG island fragments which contain expressed sequences each contain a promoter and a first exon of a gene.
32. The process of claim 31 wherein at least 20 CpG island fragments which contain expressed sequences are affixed to the solid support.

33. The process of claim 32 wherein at least 100 CpG island fragments which contain expressed sequences are affixed to the solid support.
34. The process of claim 33 wherein at least 500 CpG island fragments which contain expressed sequences are affixed to the solid support.
35. The process of claim 27 wherein the enzyme is selected from the group consisting MseI, Tsp509I, NlaIII and BfaI.
36. The process of claim 35 wherein the enzyme is MseI.
37. The process of claim 27 wherein the solid support comprises nylon, glass or silicon.
38. The process of claim 27 wherein the nucleic acid probe is isolated from normal breast, colon, ovarian, lung and prostrate tissue samples.
39. The process of claim 38 wherein the nucleic acid probe is a cDNA probe.
40. A set of amplicons, the set comprising amplified nucleic acid fragments, the nucleic acid fragments being the digestion product of a genomic nucleic acid sequence which has been digested with restriction enzymes which

digest the nucleic acid sequence into fragments in which methylated CpG islands are preserved.

41. The set of amplicons of claim 40 wherein a first restriction enzyme is selected from the group consisting of MseI, Tsp509I, NlaIII and BfaI and a second restriction enzyme is a methylation sensitive enzyme.
42. The set of amplicons of claim 41 wherein the first restriction enzyme is MseI.
43. The set of amplicons of claim 42 wherein the methylation sensitive enzyme is selected from the group consisting of BstU I, SmaI, SacII, EagI, MspI, HpaII, HhaI and BssHII.
44. The set of amplicons of claim 43 wherein the methylation sensitive enzyme is BstU I.
45. A process for isolating a set of amplicons used to identify DNA methylation patterns, said process comprising:
 - a. contacting nucleic acid sequences with an enzyme which digests the nucleic acid sequences into fragments in which CpG islands are preserved;
 - b. attaching the fragments to linker primers to form linker primer products;

- c. contacting the linker primer products with a methylation-sensitive enzyme which digests the linker primer products having unmethylated CpG dinucleotide sequences but not methylated CpG dinucleotide sequences to form a digestion product comprising methylated CpG island loci; and
 - d. amplifying the digestion product to form amplicons.
46. The process of claim 45 wherein the nucleic acid sequences are isolated from a cancer cell.
47. The process of claim 46 wherein the cancer cell is from a patient with breast cancer, prostate cancer, colon cancer, lung cancer, liver cancer and ovarian cancer.
48. The process of claim 45 wherein the nucleic acid sequences are isolated from a non-cancerous cell.
49. The process of claim 45 wherein the enzyme is selected from the group consisting of MseI, Tsp509I, NlaIII and BfaI and the methylation sensitive enzyme is selected from the group consisting of BstU I, SmaI, SacII, EagI, MspI, HpaII, HhaI and BssHII.
50. The process of claim 49 wherein the enzyme is MseI and the methylation-sensitive enzyme is BstU I.

51. A process of identifying methylation patterns in DNA from a cell sample, said process comprising:

- 5 a. isolating a first set of amplicons comprising (i)
 contacting nucleic acid sequences derived from a
 tumor cell with an enzyme which digests the nucleic
 acid sequences into fragments in which CpG islands
 are preserved; (ii) attaching the fragments to
 linker primers to form linker primer products; (iii)
10 contacting the linker primer products with a
 methylation-sensitive enzyme which digests the
 linker primer products having unmethylated CpG
 dinucleotide sequences but not methylated CpG
 dinucleotide sequences to form a digestion product
 comprising methylated CpG island loci; (iv)
15 amplifying the digestion product to form amplicons;
 and (v) labeling the amplicons;
- b. isolating a second set of amplicons comprising
 repeating (i) through (v) of step (a) wherein the
 nucleic acid sequences of (i) are nucleic acid
20 sequences derived from a non-tumor cell;
- c. contacting the first set of amplicons with a first
 screening array comprising a plurality of nucleic
 acid fragments affixed to a solid support and
 determining the presence or absence of labeled
25 amplicons bound to the plurality of nucleic acid
 fragments of the first screening array;

UMO 1523
PATENT

- 5 d. contacting the second set of amplicons with a second screening array comprising a plurality of nucleic acid fragments affixed to a solid support wherein said plurality of nucleic acid fragments of the second screening array is identical to the plurality of nucleic acid fragments of the first screening array and determining the presence or absence of labeled amplicons bound to the plurality of nucleic acid fragments of the second screening array; and

10 e. observing whether the presence or absence of the first set of amplicons bound to the plurality of nucleic acid fragments of the first screening array is the same as the presence or absence of the second set of amplicons bound to the plurality of the

15 nucleic acid fragments of the second screening array.

52. The process of claim 51 wherein the tumor cell is a breast cancer cell, prostate cancer cell, colon cancer cell, lung cancer cell, liver cancer cell and ovarian cancer cell.

53. The process of claim 51 wherein the enzyme is selected from the group comprising MseI, Tsp509I, NlaIII and BfaI and the methylation sensitive enzyme is selected from the group comprising BstU I, SmaI, SacII, EagI, MspI, HpaII, HhaI and BssHII.

5

54. The process of claim 53 wherein the enzyme is MseI and the methylation sensitive enzyme is BstU I.
55. The process of claim 51 wherein the nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second
5 screening array are derived from a CpG dinucleotide rich genomic library.
56. The process of claim 55 wherein the nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second
5 screening array are CpG dinucleotide rich fragments which comprise a sequence of at least about 200 nucleotides of which at least about 50% are guanine and cytosine.
57. The process of claim 56 wherein at least 20 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second
5 screening array.
58. The process of claim 56 wherein the plurality of nucleic acid fragments of the first screening array and the second screening array each contain a promoter and a first exon of a gene.

59. The process of claim 58 wherein at least 20 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array.
5
60. The process of claim 59 wherein at least 100 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array.
5
61. The process of claim 60 wherein at least 500 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array.
5
62. The process of claim 51 wherein the solid support of the first screening array and the solid support of the second screening array comprises nylon, glass or silicon.
63. The process of claim 51 wherein said process is used for diagnosing and monitoring the prognosis of disease associated with aberrant DNA methylation.

64. The process of claim 63 wherein said disease is breast cancer, prostate cancer, colon cancer, lung cancer, liver cancer and ovarian cancer.

65. The process of claim 64 wherein the disease is breast cancer.

66. The process of claim 51 wherein the plurality of nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.

UMO 1523
PATENT

- 5 c. contacting the first set of amplicons with a first
 screening array comprising a plurality of nucleic
 acid fragments affixed to a solid support and
 determining the presence or absence of labeled
 amplicons bound to the plurality of nucleic acid
 fragments of the first screening array;
- 10 d. contacting the second set of amplicons with a second
 screening array which comprises a plurality of
 nucleic acid fragments affixed to a solid support
 wherein the plurality of nucleic acid fragments is
 identical to the plurality of nucleic acid fragments
 of the first screening array and determining the
 presence or absence of labeled amplicons bound to
 the plurality of nucleic acid fragments of the
15 second screening array; and
- 20 e. observing whether the presence or absence of the
 first set of amplicons bound to the plurality of
 nucleic acid fragments of the first screening array
 is the same as the presence or absence of the second
 set of amplicons bound to the plurality of nucleic
 acid fragments of the second screening array.

68. The process of claim 67 wherein the nucleic acid
 sequences are derived from a cancer tumor cell.

73. The process of claim 71 wherein the plurality of nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments of affixed to the solid support of the second screening array each contain a promoter and a first exon of a gene.
5
74. The process of claim 73 wherein at least 20 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments of affixed to the solid support of the second screening array.
5
75. The process of claim 74 wherein at least 100 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments of affixed to the solid support of the second screening array.
5
76. The process of claim 75 wherein at least 500 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments of affixed to the solid support of the second screening array.
5
77. The process of claim 67 wherein the solid support of the first screening array and the solid support of the second screening array comprises nylon, glass or silicon.

UMO 1523

PATENT

69. The process of claim 68 wherein the cancer tumor cell is a breast cancer cell, prostate cancer cell, colon cancer cell, lung cancer cell, liver cancer cell and ovarian cancer cell.
70. The process of claim 67 wherein the plurality of nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array are derived from a CpG dinucleotide rich genomic library.
71. The process of claim 70 wherein the plurality of nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array are CpG dinucleotide rich fragments which comprise a sequence of at least about 200 nucleotides of which at least about 50% are guanine and cytosine.
72. The process of claim 71 wherein at least 20 nucleic acid fragments are affixed to the solid support of the first screening array and the plurality of nucleic acid fragments of affixed to the solid support of the second screening array.

78. The process of claim 67 wherein the enzyme is selected from the group comprising MseI, Tsp509I, NlaIII and BfaI and the methylation sensitive enzyme is selected from the group comprising BstU I, SmaI, SacII, EagI, MspI, HpaII, HhaI and BssHII.

79. The process of claim 78 wherein the enzyme is MseI and the methylation sensitive enzyme is BstU I.

80. The process of claim 67 wherein the plurality of nucleic acid fragments affixed to the solid support of the first screening array and the plurality of nucleic acid fragments affixed to the solid support of the second screening array are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.